News Focus
News Focus
Replies to #86270 on Biotech Values
icon url

DewDiligence

11/13/09 10:49 PM

#86271 RE: rkrw #86270

Abgenix characterized the D-mab (f/k/a/ AMG 162) royalty due from AMGN as a mid-single-digit % of sales. The XenoMouse license for D-mab happened so long ago (1999) I had to check if it was AMGN or Immunex who did the deal.